Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD–GI)
This study is a non-randomized, multi-site, pilot feasibility therapeutic trial that will enroll 20 patients diagnosed with histologically confirmed GI cancers, including colorectal.
Key Eligibility Criteria
- Diagnosis of any stage (I-IV) colorectal adenocarcinoma
- Completion of all curative-intent treatments
- Documented disease-free status by physical exam and no evidence of disease on standard imaging within 28 days of enrollment
- Positive ctDNA test result (Signatera) within 1 year of completing all curative-intent treatment and within 28 days of enrollment
Visit and Treatment Details
